McNevin Ciara S, Baird Anne-Marie, McDermott Ray, Finn Stephen P
Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, D08 W9RT Dublin, Ireland.
Department of Medical Oncology, St. James Hospital, D08 NHY1 Dublin, Ireland.
Diagnostics (Basel). 2021 Feb 19;11(2):345. doi: 10.3390/diagnostics11020345.
Prostate Cancer (PCa) is a leading cause of morbidity and mortality among men worldwide. For most men with PCa, their disease will follow an indolent course. However, advanced PCa is associated with poor outcomes. There has been an advent of new therapeutic options with proven efficacy for advanced PCa in the last decade which has improved survival outcomes for men with this disease. Despite this, advanced PCa continues to be associated with a high rate of death. There is a lack of strong evidence guiding the timing and sequence of these novel treatment strategies. This paper focuses on a review of the strategies for diagnostic and the current evidence available for treatment selection in advanced PCa.
前列腺癌(PCa)是全球男性发病和死亡的主要原因之一。对于大多数前列腺癌患者来说,他们的病情将呈惰性发展。然而,晚期前列腺癌的预后较差。在过去十年中,出现了一些对晚期前列腺癌有 proven efficacy 的新治疗选择,这改善了该病男性患者的生存结果。尽管如此,晚期前列腺癌的死亡率仍然很高。缺乏强有力的证据来指导这些新治疗策略的时机和顺序。本文重点综述晚期前列腺癌的诊断策略以及目前可用于治疗选择的证据。